贝利尤单抗联合糖皮质激素治疗儿童系统性红斑狼疮的临床研究
打开文本图片集
中图分类号：R725.932.4 文献标志码：A DOI：10.11958/20251061
Clinical study on the combination of belimumab and glucocorticoids in the treatment of systemic lupus erythematosus in children
GUO Jingxiao，YANG Yanjun， CHEN Xin， GE Lanlan，LIU Fujuan△ DepartmentofNephrology，HebeiChildren'sHospital，ShijiazhuangO5oooo，China △Corresponding Author E -mail： 772730166@qq.com
Abstract：ObjectiveToobservetheclinical eficacyofbelimumabcombinedwithglucocorticoidsinthetreatmentof childrenwithsystemiclupus erythematosus （SLE）.MethodsA totalof 64children with SLEwererandomlydivided into theobservation groupandthecontrol group，with 32cases ineach group.Thecontrol group was treated withoral prednisone tablets combined with hydroxychloroquine sulfate tablets，while the observation group was treated with belimumabon the basisof treatmentinthecontrol group.After6monthsof treatment，theclinical efcacy，systemic lupuserythematosus diseaseactivity index （SLEDAI） scores and laboratory indicators [complement C3，complement C4，immunoglobulin IgG （ IgG ），B lymphocytes，whitebloodcell count （WBC），erythrocytesedimentationrate （ESR），serum C-reactive protein （CRP）， 24-hour urine protein quantification （24h UP），serumcreatinine （SCr）and blood urea nitrogen （BUN）] were compared betweenthetwo groups.ResultsAfter6monthsoftreatment，thetotal efectiveratewas higherintheobservation group than that of the control group （93.8% us. 75.0% ， P<0.05 ）.Compared with before treatment，both groups showed lower SLEDAI scores，IgG，Blymphocytes，ESR，CRP，SCr，24h UPandBUNaftertreatment，while C3，C4levelsand WBC were higher.Moreover，the improvement of all indicators wasbeterintheobservationgroup than that inthecontrol group（ P< 0.05）.ConclusionBelimumab combined with glucocorticoidscan improve theclinical eficacy，control disease activityand enhance immune functioninchildrenwith SLE.
Key words：lupus erythematosus， systemic; glucocorticoids; inflammation; child; belimumab
系统性红斑狼疮（systemic lupuserythematosus，SLE）是一种临床较常见的自身免疫性多系统受累疾病，该病患者体内存在大量致病性自身抗体且病情易复发[1]。（剩余12049字）
